Liver enzyme monitoring in patients treated with troglitazone.

@article{Graham2001LiverEM,
  title={Liver enzyme monitoring in patients treated with troglitazone.},
  author={David J. Graham and Carol R. Drinkard and Deborah Shatin and Y. Tsong and Margaret J. Burgess},
  journal={JAMA},
  year={2001},
  volume={286 7},
  pages={
          831-3
        }
}
CONTEXT Soon after initial marketing in March 1997, troglitazone, the first thiazolidinedione antidiabetic agent, was found to cause life-threatening acute liver failure. The drug was removed from the market in March 2000. OBJECTIVE To evaluate the effect of US Food and Drug Administration (FDA) risk management efforts, including repeated labeling changes and "Dear Healthcare Professional" letters, on periodic liver enzyme monitoring of patients taking troglitazone. DESIGN, SETTING, AND… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 46 CITATIONS

Brief report: Laboratory safety monitoring of chronic medications in ambulatory care settings

  • Journal of General Internal Medicine
  • 2005
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

Epidemiology of hepatotoxicity with troglitazone: FDA Metabolic-Endocrine Drugs

DJ Graham, L. Green
  • Advisory Committee Meeting,
  • 1999
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Epidemiology of hepatotoxicity with troglitazone : FDA Metabolic - Endocrine Drugs Advisory Committee Meeting , Bethesda , Md , March 26 , 1999

DJ Graham, L Green
  • 2000

traindicated use of cisapride : impact of Food and Drug Administration regulatory action

D Shatin, DK Wysowski
  • JAMA
  • 2000

Important prescribing information for troglitazone (Rezulin) [“Dear Healthcare Professional

WR Sigmund
  • letter]. Morris Plains, NJ: Parke-Davis/ Warner Lambert; June
  • 1999
VIEW 2 EXCERPTS